. Author manuscript; available in PMC: 2020 Nov 1.

Published in final edited form as: Eur Urol Oncol. 2019 Jun 14;2(6):605–616. doi: 10.1016/j.euo.2019.05.004

Table 1 –

Study and patient characteristics

Author	Year	Institution	Country	Enrollment period	CsPCa definition	Clinical setting	Patient no.			Median age, yr (range)^a	Median PSA, ng/ml (range)^a	Median prostate volume, ml (range)^a
Author	Year	Institution	Country	Enrollment period	CsPCa definition	Clinical setting	Total	MRI-stratified pathway	SBx pathway	Median age, yr (range)^a	Median PSA, ng/ml (range)^a	Median prostate volume, ml (range)^a
Baco et al [17]	2016	Oslo University Hospital	Norway	September 2011–June 2013	GS ≥7 or MCCL ≥5 mm	Biopsy naïve	175	86	89	64 (58–69) 65 (59–69)	6.9 (5.2–9.2) 7.6 (5.9–10.4)	45 (33–60) 40 (29–52)
Bello et al [18]	2018	Hospital Universitario de Canarias	Spain	February 2015–October 2017	GS ≥7 or MCCL ≥5 mm	Biopsy naïve	303	182	121	NR	NR	NR
Kasivisvanathan et al [11]	2018	23 centers^b	11 countries^b	February 2016–August 2017	GS ≥7	Biopsy naïve	500	252	248	64.4^c 64.5	6.75 (5.16–9.35) 6.50 (5.14–8.65)	40.5 (32.0–54.8) 43.7 (33.3–60.0)
Panebianco et al [19]	2015	Sapienza University	Italy	October 2011–March 2014	GS ≥7 or percentage of CL involved with PCa ≥50%	Biopsy naïve	1140	570	570	64 (51–82)	NR	NR
Park et al [20]	2011	Samsung Medical Center	South Korea	July 2008–December 2009	GS ≥7	Biopsy naïve	85	44	41	63 (40–82) 61 (37–92)	6.1 (4.0–9.7) 5.6 (2.9–9.9)	37 (17–94) 38 (15–87)
Porpiglia et al [21]	2017	San Luigi Gonzaga Hospital	Italy	November 2014–April 2016	GS ≥7 or MCCL ≥5 mm	Biopsy naïve	212	107	105	64 (58–70) 66 (60–70)	5.9 (4.8–7.5) 6.7 (5.5–8.5)	46.2 (34.5–71.6) 45.7 (34.6–65.0)
Sciarra et al [22]	2010	Sapienza University	Italy	January 2007–January 2009	GS ≥7 (4 + 3)	Prior negative biopsy	180	90	90	63.5 (49–74)^c	6.2 (4.0–9.3) 6.0 (4.0–9.0)	45.5 (30.0–63.0) 45.0 (30.0–60.0)
Taverna et al [23]	2016	Humanitas Mater Domini	Italy	January 2013–June 2014	GS ≥7	Prior negative biopsy	200	100	100	65 ± 19^c 63 ± 15	12.63^c 13.04	NR
Tonttila et al [24]	2016	Oulu University Hospital	Finland	April 2011–December 2014	GS ≥7, >2+ cores, or MCCL ≥3 mm	Biopsy naïve	113	53	60	63 (60–66) 62 (56–67)	6.1 (4.2–9.9) 6.2 (4.0–10.7)	27.8 (23.5–36.6) 31.8 (26.1–44.3)

CL = core length; CsPCa = clinically significant prostate cancer; GS = Gleason score; MCCL = maximum cancer core length; MRI = magnetic resonance imaging; NR = not reported; PCa = prostate cancer; PSA = prostate-specific antigen; SBx =systematic transrectal ultrasound-guided biopsy; TRUS = transrectal ultrasound.

Data were provided separately for the MRI-stratified pathway (upper) and the systematic TRUS-guided biopsy pathway (lower).

Helsinki University Hospital, Finland; Centro de Urologia CDU, Argentina; Sapienza University, Italy; Mayo Clinic, Rochester, MN, USA; MRC Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland; San Raffaele Hospital, Italy; University College London and University College London Hospital, UK; Martini Klinik, Hamburg, Germany; London North West Healthcare NHS Trust, UK; Hampshire Hospitals NHS Foundation Trust, UK; Erasmus University Medical Center, Rotterdam, the Netherlands; University of Chicago, USA; Whittington Health NHS Trust, UK; CHU Lille, France; Jewish General Hospital, Montreal, Canada; Ghent University Hospital, Belgium; Princess Alexandra Hospital NHS Trust, UK; University Hospital Bern, Switzerland; Bordeaux Pellegrin University Hospital, France; Royal Free London NHS Foundation Trust, UK; Radboudumc, the Netherlands; University Hospital Heidelberg and German Cancer Research Center, Heidelberg, Germany; and Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, France.

Median.